L.E.L. Hendriks

Remon, J., Levy, A., Gille, R., Martel-Lafay, I., Bortolot, M., Hendriks, L. E. L., Faivre-Finn, C., Leighl, N., Reck, M., & Perol, M. (2026). Unresectable stage III non-small-cell lung cancer: state of the art and challenges. Nature Reviews Clinical Oncology, 23(1), 22-39. https://doi.org/10.1038/s41571-025-01080-4

De Giglio, A., Zullo, L., Di Federico, A., Cani, M., Aldea, M., Soldato, D., Dall'Olio, F. G., Mantuano, F., Sperandi, F., Favorito, V., Sadowska, A., Hendriks, L. E. L., Gorria, T., Mezquita, L., Tabbò, F., Novello, S., Gelsomino, F., Besse, B., & Ardizzoni, A. (2025). Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 =50%. ESMO Open, 10(12), Article 105897. https://doi.org/10.1016/j.esmoop.2025.105897

Ogliari, F. R., Menis, J., & Hendriks, L. E. L. (2025). Can the positive findings from POD1UM-304 improve patient care worldwide? The Lancet Respiratory medicine, 13(12), 1046-1048. https://doi.org/10.1016/S2213-2600(25)00260-7

Westra, N., Kruithof, P. D., Croes, S., van Geel, R. M. J. M., Hendriks, L. E. L., Touw, D. J., Kosterink, J. G. W., Stevens, J., Munnink, T. H. O., & Mian, P. (2025). Osimertinib Cost Minimization in Non-Small Cell Lung Cancer (NSCLC) Treatment: Hypothesis Generation for a Population Pharmacokinetic Approach for Equivalent Dose Optimization of Osimertinib in Combination With Cobicistat. Journal of Clinical Pharmacology, 65(12), 1687-1698. https://doi.org/10.1002/jcph.70085

Reguart, N., & Hendriks, L. E. L. (2025). Rethinking immunotherapy in patients with SCLC with poor performance status. The Lancet Respiratory medicine, 13(12), 1042-1043. https://doi.org/10.1016/S2213-2600(25)00290-5

Jongbloed, M., Bortolot, M., Willmann, J., Bartolomeo, V., Novoa, N. M., De Ruysscher, D. K. M., & Hendriks, L. E. L. (2025). Current Controversies and Challenges in Non-Oncogene-Addicted Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Review. JAMA Oncology, 11(11), 1385-1392. https://doi.org/10.1001/jamaoncol.2025.2891

ter Heine, R., van den Bosch, B. J. C., van Geel, R. M., van Geffen, W. H., Hendriks, L. E. L., van den Heuvel, M. M., Koele, S. E., de Langen, A. J., Oude Munnink, T. H., & van der Wekken, A. J. (2025). Optimizing lazertinib therapy through GSTM1 genotyping: a strategy to reduce excess drug exposure and potential toxicity. Cancer Chemotherapy and Pharmacology, 95(1), Article 105. https://doi.org/10.1007/s00280-025-04828-y

Ye, G., Wei, Z., Han, C., Wu, G., Wong, C., Liang, Y., Chen, X., Zhou, W., Gao, J., Liang, C., Liao, Y., Hendriks, L. E. L., Wee, L., De Ruysscher, D., Dekker, A., Zhou, H., Qi, Y., Liu, Z., & Shi, Z. (2025). AI-derived longitudinal and multi-dimensional CT classifier for non-small cell lung cancer to optimize neoadjuvant chemoimmunotherapy decision: a multicentre retrospective study. EClinicalMedicine, 89, Article 103551. https://doi.org/10.1016/j.eclinm.2025.103551

van der Wel, J. W. T., Ernst, S. M., Jebbink, M., van den Broek, D., Badrising, S. K., Steinbusch, L. C., Ruiter, G., Theelen, W. S. M. E., van Veggel, B. A. M. H., Smit, J., Dingemans, A. M., Paats, M. S., Dubbink, H. J., Hashemi, S. M. S., Radonic, T., Cohen, D., van der Wekken, A. J., ter Elst, A., Timens, W., ... de Langen, A. J. (2025). Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study. Lung Cancer, 209, Article 108783. https://doi.org/10.1016/j.lungcan.2025.108783

Kruithof, P. D., Brouns, A. J. W. M., Degens, J. H. R. J., Hendriks, L. E. L., Wong, D. R., van Geel, R. M. J. M., & Croes, S. (2025). Osimertinib Dose Optimization Guided by Therapeutic Drug Monitoring in Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Case series. Clinical Lung Cancer, 26(7), e496-e502. https://doi.org/10.1016/j.cllc.2025.05.012